FDA Adverse Event Injury Summary report: N

ENDOTAK RELIANCE G

MDR report key: 12735945 · Received November 2, 2021

Report

Report Number
2124215-2021-33638
Event Type
Injury
Date Received
November 2, 2021
Date of Event
September 30, 2021
Report Date
October 24, 2023
Manufacturer
BOSTON SCIENTIFIC CORPORATION
Product Code
LWS
PMA / PMN Number
P910073/S043
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

AS NO FURTHER INFORMATION CONCERNING THIS REPORT IS EXPECTED, OUR INVESTIGATION IS COMPLETE. THIS INVESTIGATION WILL BE UPDATED SHOULD FURTHER INFORMATION BE PROVIDED.

Additional Manufacturer Narrative · 0

AS NO FURTHER INFORMATION CONCERNING THIS REPORT IS EXPECTED, OUR INVESTIGATION IS COMPLETE. THIS INVESTIGATION WILL BE UPDATED SHOULD FURTHER INFORMATION BE PROVIDED.

Description of Event or Problem · 0

IT WAS REPORTED THAT: (B)(6) 976893. D121 214726. ESTIMATED SHOCK IMPED > 200 OHMS. TRIAD. >200 OVERALL IN TRIAD RV TO RA >200 RV TO CAN 148 RA TO CAN 159 TREND SHOWS 55 OHMS AT IMPLANT 1.5 YEARS AGO. (B)(6) 2020. 56 OHMS THE DAY AFTER IMPLANT (B)(6) 2020 111 OHMS. LATE OCT 130 OHMS (B)(6) 2021 136 OHMS. APR 112 OHMS. NOTHING ABOVE 140 OHMS N THE DAILIES UNTIL > 200 OHMS. NO SHOCKS HAVE BEEN GIVEN. BEING SEEN AT FERGUSON MD, ROLLINGTON OFFICE. JOHN WEBER IS THE REP FOR THIS ACCOUNT. CALLER FACILITY : NULL NEW ATTACHMENT(S) : NO. ADDITIONAL INFORMATION FROM EVENT RECORD 14282705 & SOURCE SYSTEM ID (B)(6). REP CALLED WITH D121 214726 IN CLINIC AND DISCOVERED SHOCK LEAD IMPEDANCE >200 OHMS PATIENT IS NOT ON NXT. 0185 DUAL COIL LEAD. ONLY AVAILABLE DATA IS FROM TODAY'S CLINIC EVAL. VECTOR BREAKDOWN SHOWED ALL THREE CONTRIBUTING LEGS HAD SIGNIFICANTLY ELEVATED IMPEDANCE MEASUREMENTS. LAST FOLLOW UP WAS ABOUT A YEAR AND A HALF AGO. HISTORICALLY SLI HAD BEEN MID50S. OCTOBER 2020 111/110/120. END OF OCT 2020 115/130/108/113. PT HAS NOT RECEIVED THERAPY. SHOCK LEAD IMPEDANCE TRENDING UPWARD OVER TIME. TS: DISCUSSED LEAD CALCIFICATION BUILD UP ON BOTH COILS, NO SUDDEN JUMPS OBSERVED IN NXT. CONSIDER MAX ENERGY SYNCHRONIZED SHOCK. DISCUSSED DIFFERENCE BETWEEN HIGHER VALUE DAILY MEASUREMENT SLI AND ACTUAL THERAPEUTIC SHOCK-DELIVERED VALUE. IF SLI EXCEEDS 145 OHMS WITH DELIVERED SHOCK, THE ENERGY IS TRUNCATED AND RESULTING SHOCK IS MONOPHASIC. JOHN WEBER IS THE SALES REP FOR THIS ACCOUNT. LOGGED ON BEHALF OF (B)(6). ACCORDING TO ADDITIONAL INFORMATION THE PATIENT PRESENTED TO THE HOSPITAL AFTER AN EPISODE OF VENTRICULAR FIBRILLATION (VF). DURING THE EPISODE, TWO ELECTRIC SHOCKS WERE DELIVERED BY THIS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) SYSTEM. THE FIRST SHOCK DID NOT CONVERT THE RHYTHM, BUT THE SECOND DID. UPON INTERROGATION, A CODE 1005 WAS FOUND FOR A SHOCK INTO AN OPEN CIRCUIT. TS RECOMMENDED DEFIBRILLATION THRESHOLD (DFT) TEST TO ENSURE SHOCK EFFICACY. NO ADVERSE PATIENT EFFECTS WERE REPORTED OUTSIDE OF THE PATIENT CONDITION. CURRENTLY, THIS LEAD REMAINS IN SERVICE.

Description of Event or Problem · 0

IT WAS REPORTED THAT: (B)(6). D121 214726. ESTIMATED SHOCK IMPED > 200 OHMS. TRIAD. >200 OVERALL IN TRIAD RV TO RA >200 RV TO CAN 148 RA TO CAN 159 TREND SHOWS 55 OHMS AT IMPLANT 1.5 YEARS AGO. (B)(6) 2020. 56 OHMS THE DAY AFTER IMPLANT (B)(6) 2020 111 OHMS. LATE OCT 130 OHMS (B)(6) 2021 136 OHMS. (B)(6) 112 OHMS. NOTHING ABOVE 140 OHMS N THE DAILIES UNTIL > 200 OHMS. NO SHOCKS HAVE BEEN GIVEN. BEING SEEN AT (B)(6). (B)(6) IS THE REP FOR THIS ACCOUNT. CALLER FACILITY : NULL NEW ATTACHMENT(S) : NO. ADDITIONAL INFORMATION FROM EVENT RECORD (B)(4) & SOURCE SYSTEM ID (B)(4). REP CALLED WITH D121 214726 IN CLINIC AND DISCOVERED SHOCK LEAD IMPEDANCE >200 OHMS PATIENT IS NOT ON NXT. 0185 DUAL COIL LEAD. ONLY AVAILABLE DATA IS FROM TODAY'S CLINIC EVAL. VECTOR BREAKDOWN SHOWED ALL THREE CONTRIBUTING LEGS HAD SIGNIFICANTLY ELEVATED IMPEDANCE MEASUREMENTS. LAST FOLLOW UP WAS ABOUT A YEAR AND A HALF AGO. HISTORICALLY SLI HAD BEEN MID50S. (B)(6) 2020 111/110/120 END OF (B)(6) 2020 115/130/108/113 PT HAS NOT RECEIVED THERAPY. SHOCK LEAD IMPEDANCE TRENDING UPWARD OVER TIME. TS: DISCUSSED LEAD CALCIFICATION BUILD UP ON BOTH COILS, NO SUDDEN JUMPS OBSERVED IN NXT. CONSIDER MAX ENERGY SYNCHRONIZED SHOCK. DISCUSSED DIFFERENCE BETWEEN HIGHER VALUE DAILY MEASUREMENT SLI AND ACTUAL THERAPEUTIC SHOCK-DELIVERED VALUE. IF SLI EXCEEDS 145 OHMS WITH DELIVERED SHOCK, THE ENERGY IS TRUNCATED AND RESULTING SHOCK IS MONOPHASIC. JOHN WEBER IS THE SALES REP FOR THIS ACCOUNT. LOGGED ON BEHALF OF (B)(6). ACCORDING TO ADDITIONAL INFORMATION THE PATIENT PRESENTED TO THE HOSPITAL AFTER AN EPISODE OF VENTRICULAR FIBRILLATION (VF). DURING THE EPISODE, TWO ELECTRIC SHOCKS WERE DELIVERED BY THIS IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (ICD) SYSTEM. THE FIRST SHOCK DID NOT CONVERT THE RHYTHM, BUT THE SECOND DID. UPON INTERROGATION, A CODE 1005 WAS FOUND FOR A SHOCK INTO AN OPEN CIRCUIT. TS RECOMMENDED DEFIBRILLATION THRESHOLD (DFT) TEST TO ENSURE SHOCK EFFICACY. NO ADVERSE PATIENT EFFECTS WERE REPORTED OUTSIDE OF THE PATIENT CONDITION. CURRENTLY, THIS LEAD REMAINS IN SERVICE. ACCORDING TO ADDITIONAL INFORMATION, THIS LEAD WAS CAPPED AND REPLACED WITH A NEW RV LEAD. NO ADDITIONAL ADVERSE PATIENT EFFECTS WERE REPORTED.

Additional Manufacturer Narrative · 1

AS NO FURTHER INFORMATION CONCERNING THIS REPORT IS EXPECTED, OUR INVESTIGATION IS COMPLETE. THIS INVESTIGATION WILL BE UPDATED SHOULD FURTHER INFORMATION BE PROVIDED.

Description of Event or Problem · 1

IT WAS REPORTED THAT THIS SYSTEM EXHIBITED AN INCREASE IN SHOCKING IMPEDANCE MEASUREMENTS WHICH WERE NOW GREATER THAN 200 OHMS. VECTOR BREAKDOWN SHOWED ALL THREE CONTRIBUTING LEGS HAD SIGNIFICANTLY ELEVATED IMPEDANCE MEASUREMENTS. A BOSTON SCIENTIFIC TECHNICAL SERVICES CONSULTANT DOCUMENTED THE CLINICAL OBSERVATIONS AND DISCUSSED TROUBLESHOOTING. NO ADVERSE PATIENT EFFECTS WERE REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1633720 ENDOTAK RELIANCE G IMPLANTABLE LEAD LWS BOSTON SCIENTIFIC CORPORATION 0185 227540

Patients

Seq Age Sex Outcome Treatment
1 51 YR Female Required Intervention| H